A citation-based method for searching scientific literature

Yong Wang, Dandan Liang, Jimin Chen, Huan Chen, Rui Fan, Ye Gao, Yongsheng Gao, Rongjie Tao, Henghui Zhang. Oncologist 2021
Times Cited: 4







List of co-cited articles
16 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development.
Guoshuang Shen, Fangchao Zheng, Dengfeng Ren, Feng Du, Qiuxia Dong, Ziyi Wang, Fuxing Zhao, Raees Ahmad, Jiuda Zhao. J Hematol Oncol 2018
92
75

Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial.
Baohui Han, Kai Li, Qiming Wang, Li Zhang, Jianhua Shi, Zhehai Wang, Ying Cheng, Jianxing He, Yuankai Shi, Yizhuo Zhao,[...]. JAMA Oncol 2018
138
50

Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors.
Yongkun Sun, Wei Niu, Feng Du, Chunxia Du, Shuting Li, Jinwan Wang, Li Li, Fengqing Wang, Yu Hao, Chuan Li,[...]. J Hematol Oncol 2016
141
50

Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor.
Chengying Xie, Xiaozhe Wan, Haitian Quan, Mingyue Zheng, Li Fu, Yun Li, Liguang Lou. Cancer Sci 2018
76
50

Pharmacokinetics and disposition of anlotinib, an oral tyrosine kinase inhibitor, in experimental animal species.
Chen-Chun Zhong, Feng Chen, Jun-Ling Yang, Wei-Wei Jia, Li Li, Chen Cheng, Fei-Fei Du, Su-Ping Zhang, Cheng-Ying Xie, Na-Ting Zhang,[...]. Acta Pharmacol Sin 2018
23
50

Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1.
Binyan Lin, Xiuming Song, Dawei Yang, Dongsheng Bai, Yuyuan Yao, Na Lu. Gene 2018
99
50

Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma.
Hai-Ying Wang, Jun-Feng Chu, Peng Zhang, Jia-Qiang Wang, Zheng Yan, Shu-Na Yao, Zhi-Hua Yao, Yan-Yan Liu. Onco Targets Ther 2020
13
50

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Roger Stupp, Warren P Mason, Martin J van den Bent, Michael Weller, Barbara Fisher, Martin J B Taphoorn, Karl Belanger, Alba A Brandes, Christine Marosi, Ulrich Bogdahn,[...]. N Engl J Med 2005
50

Targeted therapy with anlotinib for patient with recurrent glioblastoma: A case report and literature review.
Yajuan Lv, Jiandong Zhang, Fengjun Liu, Meijuan Song, Yong Hou, Ning Liang. Medicine (Baltimore) 2019
6
50

Lomustine and Bevacizumab in Progressive Glioblastoma.
Wolfgang Wick, Thierry Gorlia, Martin Bendszus, Martin Taphoorn, Felix Sahm, Inga Harting, Alba A Brandes, Walter Taal, Julien Domont, Ahmed Idbaih,[...]. N Engl J Med 2017
280
50

INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma.
Martin Van Den Bent, Marica Eoli, Juan Manuel Sepulveda, Marion Smits, Annemiek Walenkamp, Jean-Sebastian Frenel, Enrico Franceschi, Paul M Clement, Olivier Chinot, Filip De Vos,[...]. Neuro Oncol 2020
32
50

Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
Tracy T Batchelor, Dan G Duda, Emmanuelle di Tomaso, Marek Ancukiewicz, Scott R Plotkin, Elizabeth Gerstner, April F Eichler, Jan Drappatz, Fred H Hochberg, Thomas Benner,[...]. J Clin Oncol 2010
363
50

Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial.
Giuseppe Lombardi, Gian Luca De Salvo, Alba Ariela Brandes, Marica Eoli, Roberta Rudà, Marina Faedi, Ivan Lolli, Andrea Pace, Bruno Daniele, Francesco Pasqualetti,[...]. Lancet Oncol 2019
68
50

A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07).
Markus Hutterer, Martha Nowosielski, Johannes Haybaeck, Sabine Embacher, Florian Stockhammer, Thaddäus Gotwald, Bernhard Holzner, David Capper, Matthias Preusser, Christine Marosi,[...]. Neuro Oncol 2014
43
50

Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302).
Baohui Han, Kai Li, Yizhuo Zhao, Baolan Li, Ying Cheng, Jianying Zhou, You Lu, Yuankai Shi, Zhehai Wang, Liyan Jiang,[...]. Br J Cancer 2018
91
50

The Impact of Anlotinib on Brain Metastases of Non-Small Cell Lung Cancer: Post Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303).
Shunjun Jiang, Hengrui Liang, Zhichao Liu, Shen Zhao, Jun Liu, Zhanhong Xie, Wei Wang, Yalei Zhang, Baohui Han, Jianxing He,[...]. Oncologist 2020
9
50

The role of microenvironment in tumor angiogenesis.
Xianjie Jiang, Jie Wang, Xiangying Deng, Fang Xiong, Shanshan Zhang, Zhaojian Gong, Xiayu Li, Ke Cao, Hao Deng, Yi He,[...]. J Exp Clin Cancer Res 2020
28
25

Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook.
Josep Garcia, Herbert I Hurwitz, Alan B Sandler, David Miles, Robert L Coleman, Regula Deurloo, Olivier L Chinot. Cancer Treat Rev 2020
93
25

Reactive oxygen species mediate anlotinib-induced apoptosis via activation of endoplasmic reticulum stress in pancreatic cancer.
Liguo Yang, Xiaoshu Zhou, Jinrui Sun, Qianghui Lei, Qi Wang, Di Pan, Mingxing Ding, Yi Ding. Cell Death Dis 2020
10
25


Targeting angiogenesis for liver cancer: Past, present, and future.
Xiao-Dong Zhu, Zhao-You Tang, Hui-Chuan Sun. Genes Dis 2020
9
25

The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives.
Marta Sbaraglia, Elena Bellan, Angelo P Dei Tos. Pathologica 2021
12
25

Combining immunotherapy and targeted therapies in cancer treatment.
Matthew Vanneman, Glenn Dranoff. Nat Rev Cancer 2012
819
25


API5 induces cisplatin resistance through FGFR signaling in human cancer cells.
Han Sol Jang, Seon Rang Woo, Kwon-Ho Song, Hanbyoul Cho, Doo Byung Chay, Soon-Oh Hong, Hyo-Jung Lee, Se Jin Oh, Joon-Yong Chung, Jae-Hoon Kim,[...]. Exp Mol Med 2017
12
25

Anlotinib Plus S-1 for Patients with EGFR Mutation-Negative Advanced Squamous Cell Lung Cancer with PS Scores of 2-3 After Progression of Second-Line or Later-Line Treatment.
Xiao-Hong Xie, Fei Wang, Xin-Qing Lin, Yin-Yin Qin, Zhan-Hong Xie, Jie-Xia Zhang, Ming Ouyang, Cheng-Zhi Zhou. Cancer Manag Res 2020
3
33

The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib.
Christopher P Wilding, Mark L Elms, Ian Judson, Aik-Choon Tan, Robin L Jones, Paul H Huang. Expert Rev Anticancer Ther 2019
12
25

Bevacizumab treatment for radiation brain necrosis: mechanism, efficacy and issues.
Hongqing Zhuang, Siyu Shi, Zhiyong Yuan, Joe Y Chang. Mol Cancer 2019
32
25

The role of HGF/MET and FGF/FGFR in fibroblast-derived growth stimulation and lapatinib-resistance of esophageal squamous cell carcinoma.
Shin Saito, Kazue Morishima, Takashi Ui, Hiroko Hoshino, Daisuke Matsubara, Shumpei Ishikawa, Hiroyuki Aburatani, Masashi Fukayama, Yoshinori Hosoya, Naohiro Sata,[...]. BMC Cancer 2015
35
25

Anlotinib enhances the antitumor activity of radiofrequency ablation on lung squamous cell carcinoma.
Wei Zhou, Yongping Gao, Yaqi Tong, Qingjun Wu, Yunzhi Zhou, Yanming Li. Pharmacol Res 2021
6
25


Low risk to retina from sustained suppression of VEGF.
Peter A Campochiaro. J Clin Invest 2019
4
25

Apatinib as targeted therapy for sarcoma.
Feng Li, Zhichao Liao, Chao Zhang, Jun Zhao, Ruwei Xing, Sheng Teng, Jin Zhang, Yun Yang, Jilong Yang. Oncotarget 2018
10
25

Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.
Walter M Stadler, Robert A Figlin, David F McDermott, Janice P Dutcher, Jennifer J Knox, Wilson H Miller, John D Hainsworth, Charles A Henderson, Jeffrey R George, Julio Hajdenberg,[...]. Cancer 2010
194
25

Targeting the HIF2-VEGF axis in renal cell carcinoma.
Toni K Choueiri, William G Kaelin. Nat Med 2020
31
25


A phase I study investigation of metabolism, and disposition of [14C]-anlotinib after an oral administration in patients with advanced refractory solid tumors.
Yiqian Liu, Lianke Liu, Lingxiang Liu, Tongshan Wang, Lian Guo, Yixiang Wang, Zhengzhen Gao, Yongqian Shu. Cancer Chemother Pharmacol 2020
1
100

Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma.
Gangyang Wang, Mengxiong Sun, Yafei Jiang, Tao Zhang, Wei Sun, Hongsheng Wang, Fei Yin, Zhuoying Wang, Weilin Sang, Jing Xu,[...]. Int J Cancer 2019
29
25

The challenge of treating elderly patients with advanced bone and soft tissue sarcomas.
Bernd Kasper, Peter Hohenberger. Crit Rev Oncol Hematol 2020
2
50

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.
William D Tap, Robin L Jones, Brian A Van Tine, Bartosz Chmielowski, Anthony D Elias, Douglas Adkins, Mark Agulnik, Matthew M Cooney, Michael B Livingston, Gregory Pennock,[...]. Lancet 2016
347
25


Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.
Cora N Sternberg, Ian D Davis, Jozef Mardiak, Cezary Szczylik, Eunsik Lee, John Wagstaff, Carlos H Barrios, Pamela Salman, Oleg A Gladkov, Alexander Kavina,[...]. J Clin Oncol 2010
25

Soft tissue sarcoma nomograms and their incorporation into practice.
Dario Callegaro, Rosalba Miceli, Luigi Mariani, Chandrajit P Raut, Alessandro Gronchi. Cancer 2017
48
25

Pretreatment prognostic nutritional index is a prognostic marker for extensive-stage small cell lung cancer patients treated with anlotinib.
Jingjing Liu, Shuang Li, Shuang Zhang, Changliang Yang, Liang Zhang, Bin Zhang, Ying Cheng, Changli Wang. J Thorac Dis 2020
1
100

Anlotinib Combined With Chemoradiotherapy Exhibits Significant Therapeutic Efficacy in Esophageal Squamous Cell Carcinoma.
Jingzhen Shi, Yingjie Zhang, Jinzhi Wang, Jianbin Li, Zhenxiang Li. Front Oncol 2020
2
50

Therapeutic potentials of Apatinib in cancer treatment: Possible mechanisms and clinical relevance.
Nazila Fathi Maroufi, Mohammad Reza Rashidi, Vahid Vahedian, Maryam Akbarzadeh, Amir Fattahi, Mohammad Nouri. Life Sci 2020
20
25

Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells.
Lijun Liang, Kaiyuan Hui, Chenxi Hu, Yixuan Wen, Shikun Yang, Panrong Zhu, Lei Wang, Youyou Xia, Yun Qiao, Wen Sun,[...]. J Exp Clin Cancer Res 2019
29
25



Real world safety of bevacizumab in cancer patients: A systematic literature review of case reports.
Amit Dang, P Jagan Mohan Venkateswara Rao, Ravi Kishore, B N Vallish. Int J Risk Saf Med 2021
2
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.